microRNA-26a-5p Prevents Retinal Neuronal Cell Death in Diabetic Mice by Targeting PTEN

Rui Shi1, Dan-Dan Liu1, Ying Cao1

  • 1Department of Ophthalmology, Shaanxi Provincial People's Hospital, Xi'an, China.

Current Eye Research
|September 24, 2021
PubMed
Abstract

Insights

MicroRNA-26a-5p (miR-26a) protects against diabetic retinal neuronal damage by reducing PTEN expression. This finding suggests miR-26a as a potential therapeutic target for diabetic retinopathy (DR).

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Diabetology

Background:

  • Diabetic retinopathy (DR) is a leading cause of vision loss, characterized by neuronal cell death.
  • MicroRNAs (miRNAs) play crucial roles in regulating cellular processes, including neuronal survival.
  • The specific role of microRNA-26a-5p (miR-26a) in diabetic retinal neurodegeneration remains to be fully elucidated.

Purpose of the Study:

  • To investigate the role of miR-26a in early diabetic retinal neuronal cell death.
  • To elucidate the underlying molecular mechanisms by which miR-26a influences diabetic retinal pathology.

Main Methods:

  • Established a streptozotocin (STZ)-induced diabetic mouse model.
  • Administered miR-26a mimic via intravitreal injection.
  • Utilized Hematoxylin-eosin (H&E) staining, transmission electron microscopy (TEM), qRT-PCR, western blotting, and immunofluorescence assays to assess retinal structure, cell death, and molecular markers (PTEN, GFAP, IL-1β, NF-κB, VEGF).

Main Results:

  • miR-26a levels were decreased in diabetic mouse retinas; miR-26a mimic injection restored these levels.
  • miR-26a mimic treatment attenuated neuroretinal thinning, reduced ganglion cell loss, and mitigated ultrastructural damage in diabetic retinas.
  • miR-26a mimic downregulated increased PTEN expression and reduced elevated levels of GFAP, IL-1β, NF-κB, and VEGF in diabetic retinas.

Conclusions:

  • miR-26a protects retinal neurons from diabetic injury by down-regulating PTEN expression.
  • Intravitreal delivery of miR-26a shows therapeutic potential for mitigating diabetic retinal neurodegeneration.
  • miR-26a represents a promising therapeutic target for the treatment of diabetic retinopathy.